Aurora Cannabis Past Earnings Performance
Past criteria checks 0/6
Aurora Cannabis has been growing earnings at an average annual rate of 35.5%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been declining at an average rate of 1.4% per year.
Key information
35.5%
Earnings growth rate
52.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -1.4% |
| Return on equity | -5.6% |
| Net Margin | -10.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Nov 22
It's Unlikely That Aurora Cannabis Inc.'s (TSE:ACB) CEO Will See A Huge Pay Rise This Year
Aug 02Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Jun 27Why Aurora Cannabis' (TSE:ACB) Earnings Are Weaker Than They Seem
Feb 15Is Aurora Cannabis (TSE:ACB) Using Too Much Debt?
Sep 12Investors Holding Back On Aurora Cannabis Inc. (TSE:ACB)
Jun 13Is Aurora Cannabis (TSE:ACB) Using Debt Sensibly?
Jan 15Downgrade: Here's How Analysts See Aurora Cannabis Inc. (TSE:ACB) Performing In The Near Term
Nov 13Does Aurora Cannabis (TSE:ACB) Have A Healthy Balance Sheet?
Sep 22Revenue & Expenses Breakdown
How Aurora Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 297 | -30 | 161 | 3 |
| 30 Jun 24 | 279 | -30 | 160 | 3 |
| 31 Mar 24 | 270 | -55 | 157 | 4 |
| 31 Dec 23 | 266 | -116 | 174 | 4 |
| 30 Sep 23 | 262 | -153 | 174 | 5 |
| 30 Jun 23 | 248 | -195 | 167 | 5 |
| 31 Mar 23 | 224 | -793 | 170 | 6 |
| 31 Dec 22 | 212 | -1,748 | 163 | 8 |
| 30 Sep 22 | 210 | -1,757 | 180 | 8 |
| 30 Jun 22 | 221 | -1,718 | 176 | 10 |
| 31 Mar 22 | 226 | -1,233 | 185 | 11 |
| 31 Dec 21 | 231 | -381 | 189 | 12 |
| 30 Sep 21 | 238 | -607 | 188 | 13 |
| 30 Jun 21 | 245 | -692 | 195 | 11 |
| 31 Mar 21 | 257 | -2,387 | 206 | 16 |
| 31 Dec 20 | 275 | -2,359 | 241 | 18 |
| 30 Sep 20 | 263 | -3,342 | 300 | 23 |
| 30 Jun 20 | 269 | -3,231 | 346 | 26 |
| 31 Mar 20 | 299 | -1,405 | 372 | 24 |
| 31 Dec 19 | 291 | -1,430 | 397 | 22 |
| 30 Sep 19 | 290 | -385 | 376 | 17 |
| 30 Jun 19 | 246 | -294 | 365 | 15 |
| 31 Mar 19 | 168 | -211 | 327 | 10 |
| 31 Dec 18 | 119 | -72 | 253 | 7 |
| 30 Sep 18 | 77 | 174 | 187 | 5 |
| 30 Jun 18 | 55 | 72 | 110 | 2 |
| 31 Mar 18 | 42 | -13 | 69 | 1 |
| 31 Dec 17 | 31 | 7 | 45 | 0 |
| 30 Sep 17 | 23 | -4 | 31 | 0 |
| 30 Jun 17 | 18 | -13 | 25 | 0 |
| 31 Mar 17 | 13 | -16 | 19 | 0 |
| 31 Dec 16 | 8 | -13 | 13 | 0 |
| 30 Sep 16 | 5 | -10 | 8 | 1 |
| 30 Jun 16 | 1 | -6 | 6 | 1 |
| 31 Mar 16 | 0 | 0 | 5 | 1 |
| 31 Dec 15 | 0 | -3 | 4 | 1 |
| 30 Sep 15 | 0 | -10 | 4 | 1 |
| 30 Jun 15 | 0 | -10 | 4 | 0 |
Quality Earnings: ACB is currently unprofitable.
Growing Profit Margin: ACB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACB is unprofitable, but has reduced losses over the past 5 years at a rate of 35.5% per year.
Accelerating Growth: Unable to compare ACB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: ACB has a negative Return on Equity (-5.62%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aurora Cannabis Inc. is covered by 22 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Frederico Yokota Choucair Gomes | ATB Capital Markets |
| Tamy Chen | BMO Capital Markets Equity Research |
| Heather Balsky | BofA Global Research |